Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Chembiochem ; 21(4): 523-530, 2020 02 17.
Artículo en Inglés | MEDLINE | ID: mdl-31433555

RESUMEN

In the biosynthesis of the tripyrrolic pigment prodigiosin, PigB is a predicted flavin-dependent oxidase responsible for the formation of 2-methyl-3-amylpyrrole (MAP) from a dihydropyrrole. To prove which dihydropyrrole is the true intermediate, both possibilities, 5-methyl-4-pentyl-3,4-dihydro-2H-pyrrole (5 a, resulting from transamination of the aldehyde of 3-acetyloctanal) and 2-methyl-3-pentyl-3,4-dihydro-2H-pyrrole (6, resulting from transamination of the ketone), were synthesised. Only 5 a restored pigment production in a strain of Serratia sp. ATCC 39006 blocked earlier in MAP biosynthesis. PigB is membrane-associated and inactive when its transmembrane domain was deleted, but HapB, its homologue in Hahella chejuensis, lacks the transmembrane domain and is active in solution. Two colourimetric assays for PigB and HapB were developed, and the HapB-catalysed reaction was kinetically characterised. Ten analogues of 5 a were synthesised, varying in the C2 and C3 side chains, and tested as substrates of HapB in vitro and for restoration of pigment production in Serratia ΔpigD in vivo. All lengths of side chain tested at C3 were accepted, but only short side chains at C2 were accepted. The knowledge that 5 a is an intermediate in prodigiosin biosynthesis and the ease of synthesis of analogues of 5 a makes a range of prodigiosin analogues readily available by mutasynthesis.


Asunto(s)
Antibacterianos/biosíntesis , Proteínas Bacterianas/química , Gammaproteobacteria/enzimología , Monoaminooxidasa/química , Prodigiosina/biosíntesis , Serratia/enzimología , Especificidad por Sustrato
2.
Chem Commun (Camb) ; (16): 1862-4, 2008 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-18401499

RESUMEN

Analogues of prodigiosin, a tripyrrolic pigment produced by Serratia species with potent immunosuppressive and anticancer activities, have been produced by feeding synthetic analogues of the normal precursor MBC to mutants of Serratia sp. ATCC 39006 or to engineered strains of Escherichia coli; in this way it has been shown that the prodigiosin synthesising enzyme, PigC, has a relaxed substrate-specificity.


Asunto(s)
Enzimas/metabolismo , Glicosilfosfatidilinositoles/metabolismo , Prodigiosina/síntesis química , Prodigiosina/metabolismo , Enzimas/genética , Glicosilfosfatidilinositoles/clasificación , Estructura Molecular , Mutación/genética , Prodigiosina/análogos & derivados , Prodigiosina/química , Serratia/enzimología , Serratia/genética , Especificidad por Sustrato
3.
Future Microbiol ; 2(6): 605-18, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18041902

RESUMEN

Bacterial prodiginines are a family of red-pigmented, tripyrrolic compounds that display numerous biological activities, including antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive and anticancer properties. Recently, significant progress has been made in understanding the biosynthesis and regulation of bacterial prodiginines. An understanding of the biosynthesis of prodiginines will allow engineering of bacterial strains capable of synthesizing novel prodiginines through rational design and mutasynthesis experiments. Bacterial prodiginines and synthetic derivatives are effective proapoptotic agents with multiple cellular targets, and they are active against numerous cancer cell lines, including multidrug-resistant cells, with little or no toxicity towards normal cell lines. A synthetic derivative, GX15-070 (Obatoclax), developed through structure-activity relationship studies of the pyrrolic ring A of GX15, is in multiple Phase I and II clinical trials in both single and dual-agent studies to treat different types of cancer. Therefore, prodiginines have real therapeutic potential in the clinic.


Asunto(s)
Antineoplásicos/farmacología , Bacterias/química , Proliferación Celular/efectos de los fármacos , Inmunosupresores/farmacología , Prodigiosina/análogos & derivados , Línea Celular Tumoral , Ensayos Clínicos Fase I como Asunto , Ensayos Clínicos Fase II como Asunto , Regulación Bacteriana de la Expresión Génica/fisiología , Humanos , Prodigiosina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA